secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cingulate Inc. (CING)
CIK:        0001862150
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001493152-25-022132
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cingulate Q3 net loss $7.3M widens 78% YoY; NDA for CTx-1301 accepted with PDUFA May 31, 2026
--------------------------------------------------------------------------------

- Net loss $7.3M vs $4.1M in Q3 2024; operating loss $6.0M on R&D $2.8M (+99.5% YoY) and G&A $3.1M (+69.7%).
- Cash $6.1M at Sep 30, 2025; company says it needs ~$7M additional capital to fund through May 2026 PDUFA.
- FDA accepted NDA for ADHD drug CTx-1301; PDUFA target date May 31, 2026; $4.3M fee waiver granted.
- Appointed Bryan Downey as CCO; closed $6M promissory note financing with 9% interest, maturing 18 months.
- Commercial supply agreement with Bend Bio Sciences for exclusive U.S. manufacture of CTx-1301 through 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/0001493152-25-022132-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1862150/000149315225022132/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-25-022132

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer